Introduction: Organophosphorus nerve agents inhibit the enzyme, acetylcholinesterase (AChE; EC 3.1.1.7). AChE reactivators (also known as oximes) are generally used for the reactivation of an inhibited enzyme.
INTRODUCTION
Organophosphorus compounds (OPCs) are utilized in industry as softening agents, hydraulic liquids, lubricant additives, plasticizers, antioxidants, and antiflammable modifications. They are also used in animals and humans as drugs or as chemicals for the study of nervous function. Unfortunately, these compounds are also used for military purposes as chemical warfare agents (nerve agents) and as poisons exploited by terrorists [1] .
The toxicity of OPCs, especially nerve agents, is principally due to their ability to inhibit the enzyme acetylcholinesterase (AChE; EC 3.1.1.7) by phosphorylation or phosphonylation of the serine hydroxy group in its active site [2, 3] . Owing to the fact that the time required for spontaneous reactivation is comparable to the natural lifetime of AChE in the body, the inhibition is designed to be irreversible. After the inhibition process, the enzyme is not able to serve its mission to cleave neuromediator acetylcholine (ACh). The resulting accumulation of ACh at synaptic junctions over-stimulates cholinergic pathways and subsequently desensitizes cholinergic receptor sites [1, 2, 4, 10] .
Standard treatment of toxicity consists of a combination of anticholinergic drugs to counteract the effect of accumulated ACh (e.g. atropine) and AChE reactivators to reactivate OPCsinhibited AChE. Monoquaternary pralidoxime (2-PAM), bisquaternary obidoxime, and oxime HI-6 are typical members of the family of AChE reactivators ( Figure 1 ) [5] .
AChE reactivators, also known as oximes, are able to displace the organosphosphorus moiety from the inhibited enzyme. An oxime group in human blood dissociates, and the remaining oximate anion acts as a nucleophile and cleaves the bond between the enzyme and the phosphorus atom of the inhibitor. A regenerated, functional enzyme is the result of the reactivation process.
The above mentioned oximes are effective against most of the OPCs, but their therapeutic effectiveness is not completely satisfactory against other OPCs, especially nerve agents. For example, pralidoxime is unable to reactivate tabun-inhibited and cyclosarin-inhibited AChE in vitro and in vivo [6] [7] [8] . Similar results were obtained for obidoxime. Obidoxime has no ability to reactivate cyclosarin-inhibited AChE in vitro, and its potency to reactivate tabun-inhibited AChE in vitro is poor [9] . Currently the most promising AChE reactivator, oxime HI-6, is the strongest in vitro and in vivo reactivator against almost all of the nerve agents [5, 10] . Unfortunately, it has no potency to reactivate tabuninhibited AChE [6, 7] . Therefore, the replacement of currently used AChE reactivators with new and more effective oximes is a long-standing goal for the treatment of poisonings associated with highly toxic OPCs.
During the last several years, we have synthesized two new AChE reactivators (K033 and K027) at our department ( Figure 2 ) [11, 12] . Based on their potencies in reactivating rat brain AChE inhibited by several nerve agents (sarin, tabun, VX and cyclosarin) in vitro, they would be expected to be promising AChE reactivators [13, 14] .
Unfortunately, all in vitro reactivation tests were only done with the rat-brain homogenate. Although in vitro measurements with rodents are always needed because of subsequent in vivo testing with the same animal, results with another animal species are necessary. Previous studies indicated that the ability of oximes to reactivate AChE differed between species [15] . In order to obtain some new information about the potency of the new AChE reactivators (K033 and K027), we tested their abilities to reactivate pig-brain AChE inhibited by sarin. Their reactivation potencies were compared with three commonly used AChE reactivators, pralidoxime, obidoxime, and HI-6. Later, we discuss the relationship between the structure of AChE reactivators and their biological affinity.
MATERIAL AND METHODS

Chemicals
AChE reactivators (pralidoxime and obidoxime) were purchased from Leciva (Czech Republic) and Merck (Germany), respectively. HI-6 and the new oximes, K033 and K027, were synthesized at our department [11, 12, 13, 16] . The purity of all AChE reactivators was tested using TLC (DC-Alufolien Cellulose F; mobile phase n-butanol: acetic acid: water-5:1:2; Detection: Dragendorff reagent).
Sarin (GB; O-isopropyl methylflourophosphonate) was obtained from the Military Technical Institute (Brno, Czech Republic) and was 95% pure. The purity was evaluated by acidimetric titration. 
Enzyme
Pig brain homogenate was used as the appropriate source of the enzyme (AChE). The euthanasia of animals was provided by intravenous administration of embutramid in combination with mebezonium iodide and tetracaine hydrochloride (T61, Intervet International B.V., Netherlands). The whole brain was excised, washed with saline, and homogenized with distilled water (10% w/v) by the use of an Ultra-Turrax instrument (Janke-Kunkel, Germany) at 20.000 rpms for 1 min. Aliquots (2 ml) of the homogenate were stored at −25°C in a freezer and were thawed immediately prior to use.
In vitro experiments
All tested AChE reactivators were tested using a standard reactivation test described earlier by Kuca and Kassa [14] .
Percentage of the reactivation at specific concentration was calculated from the equation:
where (a 0 ) is activity of the intact enzyme, (a I ) is activity of inhibited enzyme, and (a R ) is activity of reactivated enzyme.
Reactivation potency of the tested oximes is characterized by several constants. Dissociation constant K R describes a creation of the complex of the reactivator with the inhibited enzyme. Compounds with lower values of this constant have higher affinity to the inhibited enzyme. Rate constants k R and k r describe a velocity of the reactivation of inhibited AChE. The first order rate constant k R characterizes the creation of the inhibited enzymereactivator complex. Second order rate constant k r characterizes the velocity of the overall reaction, and it is derived from the equation k r = k R /K R [16] .
A dissociation constant of the intact enzyme-reactivator K DIS was obtained by a non-linear regression from the dependence of a I on C OX by using the following equation: a I = a max C S /[C S + K M (1 + C OX /K DIS )], where, a max denotes the maximum (limiting) rate of the enzymatic reaction; C S is the substrate concentration; K M is the Michaelis constant for the hydrolysis of acetylcholine with AChE (1.9 × 10 −4 mol l −1 ); and C OX is an appropriate concentration of the tested oxime. Figure 3 describe the whole reactivation process. Oxime K033 has the highest affinity towards the intact enzyme. Its value is from 4 to 6 times lower compared to HI-6, obidoxime, and K027. Pralidoxime has the highest value of the dissociation constant K DIS , the lowest affinity towards the intact enzyme.
RESULTS
The values of all constants written in
Similar results were obtained for the dissociation constant K R , which describes affinity of the AChE reactivator towards the inhibited enzyme. Oxime HI-6 has the highest affinity. Similar values were obtained for obidoxime, K027, and K033. Pralidoxime achieved the lowest affinity towards the inhibited enzyme too. The first order rate constant k R , characterizing the decomposition of the inhibited enzyme-reactivator complex, favors pralidoxime. However, our results of the second order rate constant k r , characterizing the velocity of the whole reactivation process, shows that the most potent reactivator of sarin-inhibited AChE is oxime HI-6. The remaining values decrease as follows: obidoxime > K033 > K027 > pralidoxime.
Visualization of the relationship between the concentration of AChE reactivators and their ability to reactivate sarin-inhibited AChE is shown in Figure 3 . According to the obtained results, oxime K027 seems to be the best AChE reactivator at the concentration 10 −2 M. However, this concentration level could be toxic to humans [17] . Quite different results were obtained at the lower affinities for human relevant concentrations (10 −4 M and lower) of oximes. At the concentration 10 −4 M, HI-6 achieved the highest reactivation potency (33%) among all tested oximes. Reactivation potency of all other oximes tested at this concentration is as follows: obidoxime (23%), K027 (18%), K033 (15%) and pralidoxime (11%). All tested AChE reactivators are practically ineffective at the low concentrations (in the range from 10 −5 to 10 −7 M). Their reactivation potencies are almost similar and their values do not achieve the magnitude needed for a successful reactivation process (10%) [1] .
DISCUSSION
Current development of prophylaxis and treatment of nerve agent toxicity is focused on scavenger cholinesterases [1, 17, 18] . Unfortunately, this approach only protects against a few LD 50 nerve agents [19] . If the amount of nerve agents exceeds the tolerable dose, AChE reactivators (as the causal antidotes) are still required, and so the development of new and more potent AChE reactivators continues [20] [21] [22] [23] .
In this study, we have tested three currently used AChE reactivators (pralidoxime, obidoxime, and HI-6) in comparison with our newly developed AChE reactivators (K033 and K027) [11, 12] . We have previously tested their potencies on rat brain homogenate [13, 14] . The use of different animal species makes the effects of AChE reactivators in humans more predictable [15, 25] .
Of the reactivators tested, HI-6 is the safest AChE reactivator for use in humans. This result supports outcomes obtained from the inhibition of AChE by sarin tested on rat brain homogeate [26] . The newly synthesized oximes are very good reactivators of AChE inhibited by sarin at high concentrations. Unfortunately, they are not able to reactivate sarin-inhibited AChE at low concentrations in the range from 10 −4 to 10 −7 M.
The chemical structure of AChE reactivators affects their ability to reactivate AChE inhibited by nerve agents [6, 8] . Some of the most important moieties include the presence of the oxime group, the presence of quaternary nitrogen, and the appropriate length of the connection chain between both quaternary nitrogens [27] . All tested AChE reactivators contain the necessary structural factors.
From the substances tested, pralidoxime is the only monoquaternary reactivator nerve agent inhibited by AChE. In the molecule of pralidoxime, only one quaternary nitrogen is incorporated, and its affinity towards an intact and inhibited enzyme is too low. Compared to pralidoxime, all other tested bisquaternary AChE reactivators have a higher affinity towards both kinds of AChE. A satisfactory reactivation process depends on the nucleophile used. Currently, oximate anion is the most suitable nuclephilic group. There are many research studies dealing with the quantitative structure activity relationship (QSAR) [28] [29] [30] . QSAR uses structural patterns (position and number of oxime groups, presence and number of quaternary nitrogen) and physico-chemical properties (partition coefficient, pK a ) for predicting the biological activity of a proposed AChE reactivator [31] . However, none of them are able to accurately predict the most active, desired structure. This is the reason the in vitro method remains the main technique for quick and cheap evaluation of new AChE reactivators.
CONCLUSION
Using our in vitro method, we have evaluated the potency of two newly developed AChE reactivators (K033 and K027) and compared them to currently used AChE reactivators. Pig brain homogenate was used as a suitable source of the enzyme. According to our results, if compared with our previous data, the reactivation process is species dependent. Because the reactivation process is species dependent, it should be taken into account that results obtained for one animal species will not be achieved for other animal species (species limitation). Another limitation is in vitro versus in vivo testing. This limitation can be solved by repetition of these experiments in vivo on different animal species. These experiments on larger animals are expensive, and only a few laboratories throughout the world are equipped and interested in the experiments. Moreover, such in vivo experiments on humans are not approved for ethical reasons. For all these reasons, comparative in vitro studies are still needed. 
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